Related references
Note: Only part of the references are listed.Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Lawrence G. Lum et al.
CLINICAL CANCER RESEARCH (2015)
Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial
Edward A. Stadtmauer et al.
BLOOD (2011)
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma
Aaron P. Rapoport et al.
BLOOD (2011)
In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells
Archana Thakur et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials
Donald A. Berry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Induction of Specific Cellular and Humoral Responses Against Renal Cell Carcinoma After Combination Therapy With Cryoablation and Granulocyte-Macrophage Colony Stimulating Factor: A Pilot Study
Archana Thakur et al.
JOURNAL OF IMMUNOTHERAPY (2011)
IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments
Michelle R. Simpson-Abelson et al.
CLINICAL IMMUNOLOGY (2009)
Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation
RC Grabert et al.
CLINICAL CANCER RESEARCH (2006)
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
AP Rapoport et al.
NATURE MEDICINE (2005)
T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro
JM Gall et al.
EXPERIMENTAL HEMATOLOGY (2005)
Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors
M Sen et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)